atorvastatin has been researched along with Syndrome in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 31 (83.78) | 29.6817 |
| 2010's | 5 (13.51) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Liu, X; Sun, Y; Yu, W; Yuan, L | 1 |
| Batista, ML; Bedard, AH; Birbrair, A; Bueno, LL; Correa, VA; Farmer, SR; Franco, FO; Guilherme, A; Henriques, F; Knobl, P; Lopes, MA; Peres, SB; Santos, KB | 1 |
| Alvarez-Mendez, A; Beamonte-Vela, BN; García Carretero, R; Silvano-Cocinero, JD | 1 |
| Chouksey, D; Dani, R; Dube, M; Dubey, A | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Dougu, N; Nukui, T; Taguchi, Y; Takashima, S; Tanaka, K; Toyoda, S | 1 |
| Bar-Or, A; Calabresi, PA; Cohen, JA; Cross, A; Ding, L; Goodman, A; Iklé, D; Kachuck, N; Kita, M; Kopetskie, H; Mass, M; Miller, A; Mokhtarani, M; Murphy, S; Pelletier, D; Preiningerova, J; Racke, M; Rosenberg, E; Schwid, S; Spencer, C; Stüve, O; Vollmer, T; Waubant, E; Weinstock-Guttman, B; Zamvil, SS | 1 |
| Duffy, SJ; Gokce, N; Holbrook, M; Kahn, D; Keaney, JF; Palmisano, J; Thomas, S; Tomasian, D; Vita, JA | 1 |
| Böhm, M; Fries, R | 1 |
| Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H | 1 |
| Correia, LC; D'Oliveira, A; Esteves, JP; Lima, JC; Magalhães, LP; Passos, LC; Rocha, MS; Spósito, AC | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Slavina, NN; Vaulin, NA | 1 |
| Ganz, P; Kinlay, S; Leslie, SJ; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Arikian, S; Ganz, P; Schwartz, GG; Waters, D | 1 |
| Casciano, R; Olsson, A; Stern, L; Svangren, P | 1 |
| Lange, AP; Szucs, TD | 1 |
| McGowan, MP | 1 |
| Cannon, CP; Ray, KK | 1 |
| Casciano, R; Gómez-Gerique, JA; Rejas, J; Stern, L | 1 |
| Schwartz, GG | 1 |
| Badaracco, R; Brizuela, M; Cialzeta, JR; Doval, H; Farías, EF; Franciosi, V; Macin, SM; Medina, F; Perna, ER; Tajer, C | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Jackson, G; McCabe, CH; Ray, KK; Sacks, FM; Tonkin, AM | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Ridker, PM; Rifai, N; Skene, AM | 1 |
| Amyot, R; Arnold, M; Bonafede, N; Cannon, CP; Dupuis, J; Lonn, E; Ricci, J; Rouleau, JL; Roux, R; Tardif, JC; Title, LM; Woo, A | 1 |
| Fonarow, GC | 1 |
| Qi, SS; Shen, XQ; Zeng, GF; Zhou, HN; Zhou, SH; Zhou, T | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Braunwald, E; Cannon, CP; Jarolim, P; McCabe, CH; Morrow, DA; Ray, KK; Sabatine, MS; Scirica, BM; Shui, A | 1 |
| Braunwald, E; Giugliano, RP | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Yamagishi, M | 1 |
| Alhan, CC; Avkaroğullari, M; Cayli, M; Demir, M; Demirtaş, M; Dönmez, Y; Inal, T; Kanadaşi, M; Koç, M; San, M; Usal, A | 1 |
| Chyrchel, M; Dubiel, JS; Dudek, D; Dziewierz, A; Legutko, J; Rakowski, T; Rzeszutko, L | 1 |
| Jamieson, MJ; Luo, D; Olsson, AG; Schwartz, GG; Szarek, M | 1 |
| Colonna, G; Di Sciascio, G; Fischetti, D; Miglionico, M; Montinaro, A; Pasceri, V; Patti, G; Sardella, G | 1 |
| De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C | 1 |
| Acevedo, M; Francis, G; Lauer, MS; Sprecher, DL | 1 |
5 review(s) available for atorvastatin and Syndrome
| Article | Year |
|---|---|
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Ischemia; Pravastatin; Pyrroles; Syndrome; Treatment Outcome | 2005 |
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Topics: Acute Disease; Atorvastatin; Cardiac Output, Low; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Natriuretic Peptide, Brain; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome | 2006 |
The year in non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Prognosis; Pyrroles; Risk Assessment; Stents; Syndrome; Thrombolytic Therapy; Ticlopidine | 2006 |
16 trial(s) available for atorvastatin and Syndrome
| Article | Year |
|---|---|
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Brain; Canada; Confounding Factors, Epidemiologic; Contrast Media; Double-Blind Method; Female; Gadolinium; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Odds Ratio; Pyrroles; Research Design; Syndrome; Treatment Outcome; United States | 2012 |
Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Blood Flow Velocity; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Muscle, Smooth, Vascular; Nitroglycerin; Pyrroles; Syndrome; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2003 |
Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Syndrome; Treatment Outcome | 2003 |
[Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Electrocardiography; Female; Heptanoic Acids; Homeostasis; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Syndrome; Time Factors | 2003 |
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Topics: Acute Disease; Aged; Angina, Unstable; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Pyrroles; Serum Amyloid A Protein; Syndrome; Troponin | 2003 |
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.
Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment | 2004 |
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Acute-Phase Proteins; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Female; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Secondary Prevention; Syndrome | 2005 |
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; Time Factors | 2005 |
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors; Syndrome | 2005 |
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial).
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Syndrome; Ultrasonography; Vasodilation | 2005 |
The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome.
Topics: Acute Disease; Atorvastatin; C-Reactive Protein; Coronary Disease; Female; Heptanoic Acids; Humans; Lipid Metabolism; Middle Aged; Peroxidase; Pyrroles; Syndrome | 2006 |
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2006 |
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Myocardial Ischemia; Pyrroles; Quinolines; Research Design; Syndrome | 2006 |
Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Retrospective Studies; Syndrome; Treatment Outcome | 2007 |
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Syndrome; Time Factors; Treatment Outcome | 2007 |
16 other study(ies) available for atorvastatin and Syndrome
| Article | Year |
|---|---|
Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity.
Topics: Atorvastatin; Humans; Immunity; Liver; Lupus Erythematosus, Systemic; Retrospective Studies; Syndrome | 2022 |
Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia Syndrome.
Topics: 3T3-L1 Cells; Adipose Tissue; Adiposity; Animals; Atorvastatin; Cachexia; Carcinoma, Lewis Lung; Disease Models, Animal; Gene Deletion; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Survival Analysis; Syndrome; Toll-Like Receptor 4; Tumor Cells, Cultured | 2018 |
Behavioural changes as the first manifestation of a silent frontal lobe stroke.
Topics: Aged; Atorvastatin; Brain; Cerebral Infarction; Frontal Lobe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Neuroimaging; Problem Behavior; Stroke; Syndrome; Tomography, X-Ray Computed | 2019 |
Twenty-and-a-half syndrome: a case report.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Brain; Brain Ischemia; Cranial Nerve Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Middle Aged; Paresis; Physical Therapy Modalities; Platelet Aggregation Inhibitors; Ramipril; Stroke; Syndrome | 2019 |
[Case of branch atheromatous disease presenting capsular warning syndrome].
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atorvastatin; Dextrans; Diffusion Magnetic Resonance Imaging; Drug Therapy, Combination; Heptanoic Acids; Humans; Infusions, Intravenous; Ischemic Attack, Transient; Magnetic Resonance Angiography; Male; Middle Aged; Pyrroles; Recurrence; Syndrome; Thrombolytic Therapy; Tissue Plasminogen Activator | 2010 |
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Drug Utilization; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Registries; Stroke; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Cost-Benefit Analysis; Economics, Pharmaceutical; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Secondary Prevention; Syndrome | 2003 |
A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Health Care Costs; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Retrospective Studies; Sweden; Syndrome; Time Factors; Treatment Outcome | 2004 |
[Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
Topics: Acute Disease; Adolescent; Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cost Savings; Cost-Benefit Analysis; Costs and Cost Analysis; Diagnosis-Related Groups; Double-Blind Method; Germany; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Patient Compliance; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Syndrome; Time Factors | 2004 |
A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Cost Savings; Cost-Benefit Analysis; Diagnosis-Related Groups; Double-Blind Method; Economics, Pharmaceutical; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Spain; Syndrome; Time Factors; Treatment Outcome | 2004 |
Statins in acute coronary syndromes: the sooner, the better?
Topics: Acute Disease; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Secondary Prevention; Syndrome | 2005 |
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome | 2005 |
The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Serum Amyloid A Protein; Statistics as Topic; Syndrome; Treatment Outcome; Triglycerides | 2006 |
Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Premedication; Pyrroles; Retrospective Studies; Syndrome; Treatment Outcome | 2006 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome | 2008 |
Routine statin treatment after acute coronary syndromes?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Patient Discharge; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2002 |